Company intelligence / Profile preview

Actimed Therapeutics

Ascot, Berkshire, United Kingdomactimedtherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Actimed Therapeutics is developing treatments for cachexia and muscle wasting conditions. Their lead product, S-pindolol benzoate (ACM-001.1), has generated promising proof of concept Phase 2a clinical data in cachexia patients. The company received IND approval from FDA for S-pindolol benzoate in August 2023 for cancer cachexia treatment. Their second asset, S-oxprenolol (ACM-002), is being developed for muscle wasting in ALS and received Orphan Drug Designation from the FDA in 2024.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

4 assets

s-pindolol benzoate

3 more assets in the full pipeline.

Request access →

Partnerships

Faraday Pharmaceuticals

Beyond the preview

Go deeper on Actimed Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actimed Therapeutics.

Explore the full profile